Seven members of the PTC Therapeutics team joined 11 HD-CAB team members for an advisory board on the 3rd November. Sian O’Neill, Senior Director of Patient Engagement EMEA & AP wrote following the meeting to say “Thank you again for the opportunity to participate in the 1st HD-CAB. It was a pleasure to meet such an amazing group of people. The CAB team has pushed the PTC team into overdrive! The real and honest sharing of the reality of HD has generated a lot of questions and dare I say shifted the thought process for our team.”
الأخبار
SOM Biotech completes the recruitment process in the Phase IIb study of the treatment of chorea in Huntington’s disease
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a قراءة المزيد...…